New data from Google’s longevity play Calico and the neuro-focused biotech Denali Therapeutics showed neither of their ALS ...

Eli Lilly joins FDA lawsuit over tirzepatide shortage listing, as Outsourcing Facilities Association challenges removal of ...

Immuneering's MEK inhibitor IMM-1-104 shows positive Phase 2a results in pancreatic cancer with 43% response rate when ...

Pfizer has re-upped its drug discovery deal with AI startup PostEra to develop small molecule drugs and new warheads for antibody-drug conjugates, a major area of focus for the drugmaker ...

Novo Nordisk partners with Variant Bio, paying up to $50M upfront for metabolic disease targets. Some funds will support Indigenous communities that provided data.

Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for monthly dosing and no titration requirement.

Johnson & Johnson said its recently approved Rybrevant and Lazcluze combination therapy topped Tagrisso on overall survival ...

XyloCor raises $67.5M Series B led by Jeito Capital for XC001 gene therapy trials in cardiac patients. CEO Al Gianchetti says ...

Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...

Avenzo Therapeutics pays $50M upfront to DualityBio for rights to bispecific antibody-drug conjugate DB-1418. Deal follows ...

Candid Therapeutics commits $925M for WuXi Biologics' T cell engager rights. CEO Ken Song aims for human trials in 2026, ...

Highlander Health, the clinical trial startup co-founded by former Verily execs Amy Abernethy and Brad Hirsch, is acquiring ...